Therefore, AF patients undergoing PCI require both OAC for AF-related embolic event prophylaxis and DAPT with aspirin and a P2Y12 inhibitor to face stent thrombosis and atherosclerotic progression; consequently, their management becomes challenging [3,14,58,59,60]. The gene discussed is P2RY12; the disease is atrial fibrillation.